Amgen
Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Breaking New Ground With Science. With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
Jun 7, 2021 · FDA approves Biogen Alzheimer’s treatment. It is a reflection of “two decades of no innovation” and will also allow the company to further invest in its pipeline of drugs for other diseases ...
Jan 7, 2023 · Jan 7 (Reuters) - The U.S. Food and Drug Administration on Friday approved the Alzheimer's drug lecanemab developed by Eisai Co Ltd (4523.T) and Biogen Inc (BIIB.O) for patients in the earliest...
May 22, 2024 · Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences. May 22, 2024. PDF Version. Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases.
Biogen South Africa is a premium wellness brand. Offering high quality vitamin & supplement products across a wide range of categories.
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities.
The potential to transform the lives of patients is what drives us at Biogen. As a leading global biotechnology company, we work toward those once-in-a-lifetime moments that could become a historic point in our pursuit of innovative treatments.
May 22, 2024 · Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its older multiple sclerosis drugs face...
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose pf serving humanity through science while ...
2 days ago · Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases.
Jan 11, 2021 · The study aims to identify digital biomarkers to help monitor cognitive performance and health including potentially detecting mild cognitive impairment, an early indicator of certain forms of dementia such as Alzheimer’s disease.
Sep 1, 2009 · BIOGEN (SINGAPORE) PTE. LTD. was incorporated on 1 September 2009 (Tuesday) as a Private Company Limited by Shares in Singapore. The Company current operating status is dissolved - members' voluntary winding up with registered address at PARKVIEW SQUARE.
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease.
Jan 31, 2024 · Biogen will focus on LEQEMBI® (lecanemab-irmb) with Eisai and advancing potential new modalities to address the multiple pathologies of the disease and unmet patient needs. A plan for patients participating in clinical trials or on commercially available treatment is in place.
Biogen er en førende global biotek-virksomhed med fokus på innovativ forskning indenfor alvorlige og komplekse sygdomsområder. Biogens pipeline omfatter potentielle behandlinger indenfor neurologi, neuropsykiatri, immunologi og sjældne sygdomme.
At Biogen we achieve excellence together, connected by a greater purpose to improve the lives of patients. Hear from the best and brightest at Biogen on what inspires them every day and why you should join our team.
5 days ago · Biogen Pharmach Share Price: Find the latest news on Biogen Pharmach Stock Price. Get all the information on Biogen Pharmach with historic price charts for NSE / BSE.
If you wish to report any compliance concerns regarding Biogen or any of its employees or contractors, you may do so in writing at the address provided below or confidentially and anonymously, where permitted by local law, by using the Compliance Helpline.
